Molecular & Cellular Toxicology

The Korean Society of Toxicogenomics and Toxicoproteomics (대한독성유전 단백체학회)
권호 표지

CYP2D6 P34S Polymorphism and Mirtazapine Responses in Koreans with Major Depression

  • Jeon, Si-On (Department of Psychiatry, College of Medicine, Korea University) ;
  • Chang, Hun-Soo (Pharmacogenomic Research Center for Psychotropic Drugs, Korea University) ;
  • Lee, Hwa-Young (Department of Psychiatry, College of Medicine, Korea University) ;
  • Ham, Byung-Joo (Department of Psychiatry, College of Medicine, Korea University) ;
  • Kang, Rhee-Hun (Department of Psychiatry, College of Medicine, Korea University) ;
  • Jeong, Yoo-Jung (Pharmacogenomic Research Center for Psychotropic Drugs, Korea University) ;
  • Lee, Min-Soo (Department of Psychiatry, College of Medicine, Korea University)
  • Published : 2009.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Drug metabolism is a critical determinant of the therapeutic and adverse effects of many psychotropic drugs. The metabolism depends on the pharmacokinetics of a drug, which includes its absorption, distribution, and elimination. Psychotropic drugs are metabolized mainly by cytochrome P450 (CYP) enzymes; about 20 of these enzymes exist and they are often responsible for the rate-limiting step of drug metabolism. CYP2D6 is the best-characterized P450 enzyme that exhibits polymorphism in humans. This study determined the relationship between the CYP2D6*10 (P34S) polymorphism and the response to mirtazapine in 153 Koreans with major depressive disorder (MDD). The genotype frequencies were compared using logistic regression analysis, and between-genotype differences in the decrease in the 21-item Hamilton Depression (HAMD21) score over the 12-week treatment period were analyzed using a linear regression analysis. The proportion of remitters was lower in patients with MDD possessing the S allele than in P allele carriers after 2 weeks of mirtazapine treatment. Similarly, the reductions in the HAMD21 and Clinical Global Impression (CGI) scores in S allele carriers were smaller than those in patients with the P allele after 2 weeks of mirtazapine treatment. In the analysis of depression symptoms, the sleep and delusion scores had smaller reductions in S allele carriers. Based on the Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS), the psychic adverse effects of mirtazapine were associated with CYP2D6 P34S, while weight gain was not. These results suggest that CYP2D6 P34S affects the outcome of mirtazapine treatment in patients with MDD, and that this polymorphism may be a good genetic marker for predicting the clinical outcome of mirtazapine treatment.

Keywords

References

  1. Nebert, D. W. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? (Editorial). Am J Hum Genet 60:265-271 (1997)
  2. Brosen, K. Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie 59: 5-12 (2004) https://doi.org/10.2515/therapie:2004003
  3. Kirchheiner, J. et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9:442-473 (2004) https://doi.org/10.1038/sj.mp.4001494
  4. Yin, O. Q. et al. Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients. J Clin Psychopharmacol 26:367-372 (2006) https://doi.org/10.1097/01.jcp.0000227355.54074.14
  5. Grasmader, K. et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. European Journal of Clinical Pharmacology 60:329-336 (2004) https://doi.org/10.1007/s00228-004-0766-8
  6. Rau, T. et al. Cyp2d6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants- a pilot study. Clinical Pharmacology & Therapeutics 75:386-393 (2004) https://doi.org/10.1016/j.clpt.2003.12.015
  7. Murphy, G. M., Jr, Kremer, C., Rodrigues, H. E. & Schatzberg, A. F. Pharmacogenetics of antidepressant medication intolerance. American Journal of Psychiatry 160:1830-1835 (2003) https://doi.org/10.1176/appi.ajp.160.10.1830
  8. Suzuki, Y., Sawamura, K. & Someya, T. Polymorphisms in the 5-hydroxytryptamine 2A receptor and cytochrome P4502D6 genes synergistically predict fluvoxamine-induced side effects in Japanese depressed patients. Neuropsychopharmacology 31: 825-831 (2006) https://doi.org/10.1038/sj.npp.1300919
  9. Mrazek, D., Smoller, J. & de Leon, J. Incorporating pharmacogenetics into clinical practice: Reality of a new tool in psychiatry. CNS Spectr 11:1-13 (2006)
  10. De Boer, T. The effects of mirtazapine on central nora- drenergic and serotonergic neurotransmission. Int Clin Psychopharmacol 10(Suppl 4):19-23 (1995)
  11. De Boer, T. & Ruigt, G. S. F. The selective 2-adrenoceptor antagonist mirtazapine (Org 3770) enhances noradrenergic and 5-HT1A mediated serotonergic neurotransmission. CNS Drugs 4(Suppl 1):29-38 (1995) https://doi.org/10.2165/00023210-199500041-00006
  12. De Boer, T., Ruigt, G. S. F. & Berendsen, H. H. G. The alpha2-selective adrenoceptor antagonist org 3770 (mirtazapine, Remeron${\circledR}$) enhances noradrenergic and serotonergic transmission. Hum Psychopharmacol 10(S2):S107-S118 (1995) https://doi.org/10.1002/hup.470100805
  13. De Montigny, C., Haddjeri, N., Mongeau, R. & Blier, P. The effects of mirtazapine on the interactions between central noradrenergic and serotonergic systems. CNS Drugs 4(Suppl 1):13-17 (1995) https://doi.org/10.2165/00023210-199500041-00004
  14. Haddjeri, N., Blier, P. & de Montigny, C. Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine. Int Clin Psychopharmacol 10(Suppl 4):11-17 (1995)
  15. Anttila, S. A. & Leinonen, E. V. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Reviews 7:249-64 (2001) https://doi.org/10.1111/j.1527-3458.2001.tb00198.x
  16. Fawcett, J. & Barkin, R. L. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord 51:267-285 (1998) https://doi.org/10.1016/S0165-0327(98)00224-9
  17. Nutt, D. J. Tolerability and safety aspects of mirtazapine. Hum Psychopharmacol 17(Suppl 1):S37-41 (2002) https://doi.org/10.1002/hup.388
  18. Timmer, C. J., Sitsen, J. M. & Delbressine, L. P. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 38:461-474 (2000) https://doi.org/10.2165/00003088-200038060-00001
  19. Droll, K. et al. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. Pharmacogenetics 8:325-333 (1998) https://doi.org/10.1097/00008571-199808000-00006
  20. Duman, R. S. & Charney, D. S. Cell atrophy and loss in major depression. Biol Psychiatry 45:1083-1084 (1999) https://doi.org/10.1016/S0006-3223(99)00057-8
  21. Maisonpierre, P. C. et al. Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizations. Genomics 10:558-568 (1991) https://doi.org/10.1016/0888-7543(91)90436-I
  22. Duman, R. S., Heninger, G. R. & Nestler, E. J. A molecular and cellular theory of depression. Arch Gen Psychiatry 54:597-606 (1997) https://doi.org/10.1001/archpsyc.1997.01830190015002
  23. Tsai, S. J., Cheng, C. Y., Yu, Y. W., Chen, T. J. & Hong, C. J. Association study of a brain-derived neurotrophic- factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am J Med Genet B Neuropsychiatr Genet 123B:19-22 (2003) https://doi.org/10.1002/ajmg.b.20026
  24. Spina, E., Santoro, V. & D'Arrigo, C. Clinically relevant pharmacokinetic drug interactions with secondgeneration antidepressants: An update. Clin Therapeutics 30:1206-1227 (2008) https://doi.org/10.1016/S0149-2918(08)80047-1
  25. Sachse, C. B. J., Bauer, S. & Roots, I. Cytochrome 450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284-295 (1997)
  26. Nishida, Y., Fukuda, T., Yamamoto, I. & Azuma, J. CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics 10:567-570 (2000) https://doi.org/10.1097/00008571-200008000-00010
  27. Lee, S.-Y. et al. Sequence-based CYP2D6 genotyping in the Korean population. Ther Drug Monit 28:382-387 (2006) https://doi.org/10.1097/01.ftd.0000211823.80854.db
  28. Ji, L. et al. Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese. Clin Chem 48:983-988 (2002)
  29. Bijl, M. J. et al. Association between the CYP2D6*4 polymorphism and depression or anxiety in the elderly. Pharmacogenomics 10:541-547 (2009) https://doi.org/10.2217/pgs.09.9
  30. Serretti, A. et al. Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. Int Clin Psychopharmacol 24:250-256 (2009) https://doi.org/10.1097/YIC.0b013e32832e5b0d
  31. Chou, W. H. et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol 20:246-251 (2000) https://doi.org/10.1097/00004714-200004000-00019
  32. Laimer, M. et al. Effect of mirtazapine treatment on body composition and metabolism. J Clin Psychiatry 67:421-424 (2006) https://doi.org/10.4088/JCP.v67n0313
  33. Gorwood, P. Genetic association studies in behavioral neuroscience, in Handbook of molecular-genetic techniques for brain and behavior research, W. Cruzio and R. Gerlai, Editors. Elsevier: Amsterdam. 113-121(1999)
  34. Kim, J. W. Association study and the population admixture, in Human Neurobehavioral Genetics in the 21st Century. Korean Society of Biological Psychiatry: Seoul, Korea (2003)
  35. Frank, E. et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 48:851-855 (1991) https://doi.org/10.1001/archpsyc.1991.01810330075011
  36. Serretti, A. et al. SSRIs antidepressant activity is influenced by G beta 3 variants. Eur Neuropsychopharmacol 13:117-122 (2003) https://doi.org/10.1016/S0924-977X(02)00154-2
  37. Faul, F., Erdfelder, E., Buchner, A. & Lang, A. G. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods 41:1149-1160 (2009) https://doi.org/10.3758/BRM.41.4.1149